Management of the metabolic effects of HIV and HIV drugs.
about
Dysfunctional adipose tissue and low-grade inflammation in the management of the metabolic syndrome: current practices and future advancesFatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIVIncreased cardiovascular disease risk in the HIV-positive population on ART: potential role of HIV-Nef and TatThe end of AIDS: HIV infection as a chronic diseaseAvailability of data on adverse reactions to antiretroviral drugs in medical charts according to the Naranjo algorithm: an example of a Brazilian historical cohort.Pathogenesis and treatment of HIV infection: the cellular, the immune system and the neuroendocrine systems perspective.Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: a randomized, double-blind, placebo-controlled, factorial trialPlasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors.Insulin-like growth factors and related proteins in plasma and cerebrospinal fluids of HIV-positive individuals.Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat.Omega-3 fatty acid therapy reduces triglycerides and interleukin-6 in hypertriglyeridemic HIV patientsEffects of a 2-Year Supervised Exercise Program Upon the Body Composition and Muscular Performance of HIV-Infected Patients.Applications and limitations of inflammatory biomarkers for studies on neurocognitive impairment in HIV infection.Metabolic Disorders in HIV-Infected Adolescents Receiving Protease Inhibitors.HIV and the heart: the impact of antiretroviral therapy: a global perspective.Risk of coronary heart disease in patients with HIV infection.Cardiovascular disease associated with the human immunodeficiency virus: an update.Epicardial adipose tissue volume and cardiovascular risk indices among asymptomatic women with and without HIV.Endocrinological aspects of HIV infection.End-of-Life Care and Bereavement Issues in Human Immunodeficiency Virus-AIDS.Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin.Adiponectin and the steatosis marker Chi3L1 decrease following switch to raltegravir compared to continued PI/NNRTI-based antiretroviral therapy.
P2860
Q28070056-CDDDE28B-CD39-4696-B741-9DBF1C1CD2FDQ28079826-27EB49BA-EA44-4011-830C-5C9A6F4B4E27Q28080948-C58C546A-1F76-4D53-A03A-C8CCE8E12DDFQ28300749-A63E06CD-9321-40CE-9956-698933B29932Q30795747-1C05D0E5-BB91-4A03-A43A-EE0F48E6E828Q34650866-CA437E62-8CDA-48D9-9712-5D6A5AF90186Q34674697-774F7A66-9C54-445F-BF8F-3F2C60806059Q34704820-A8A5C9C5-60DB-4775-8F24-6C2AD94DDE32Q35530481-7AB58C56-B75B-40F8-837C-F15DC8683697Q35803315-0ECF270E-3A51-4EBA-9F80-A634441295BCQ35903682-527B6FA0-B1C6-4595-8FAE-92B2C0ADA9A1Q36282508-579527EB-270C-40CC-812C-FABF4A9EB548Q37467991-85D42BAB-114D-4B86-99E0-FB3A15F7D90EQ37673041-1989F564-E89C-40C0-A14C-95FB8D57157FQ38152708-4657732D-9F42-430A-A88B-9B53DF0923ACQ38261508-F56CE5FE-18CB-49BE-9188-C572D767386DQ41751842-A3924CAF-F2EF-4DFF-A7B4-B22C7D2C7108Q41996168-5FA48D71-6FB4-438B-822B-570F38845E7DQ47219853-3D60A1E2-C426-40A2-94DD-9D27CA158637Q47549642-7E0687A1-5D0E-408F-BC86-7DBCDC54FA65Q51750715-AA516FC2-9958-4A05-A265-39A2B145C4A8Q55238731-9AD45721-F115-4AF6-9C3A-31F98D86B30F
P2860
Management of the metabolic effects of HIV and HIV drugs.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Management of the metabolic effects of HIV and HIV drugs.
@ast
Management of the metabolic effects of HIV and HIV drugs.
@en
type
label
Management of the metabolic effects of HIV and HIV drugs.
@ast
Management of the metabolic effects of HIV and HIV drugs.
@en
prefLabel
Management of the metabolic effects of HIV and HIV drugs.
@ast
Management of the metabolic effects of HIV and HIV drugs.
@en
P2860
P356
P1476
Management of the metabolic effects of HIV and HIV drugs.
@en
P2093
Marshall J Glesby
Todd T Brown
P2860
P2888
P356
10.1038/NRENDO.2011.151
P577
2011-09-20T00:00:00Z